top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

Publications

 

  1. Isaacs JS, Chen P, Garza A, Hansen MF, Barrett J, and Weissman BE (1997). Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids. Oncogene, 14, 1669-1678. View in: PubMed                                                                                                                                                  

  2. Isaacs JS, Chiao C, Merrick, BA, Selkirk, JK, Barrett, J.C., and Weissman, BE (1997) p53 dependent p21 induction following IR without concomitant p53 induction in a human PNET cell line. Cancer Research, 57, 2986-2992. View in: PubMed                                                                                

  3. Isaacs JS, Hardman R, Carmen T, Barrett JC, and Weissman BE (1998) Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines. Cell Growth & Differ., 9, 545-555. Cover Article. View in: PubMed                                                                                                                                 

  4. Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, and Barrett, JC. (1999). Two post-transcriptional pathways that regulate p21Cip1/Waf1/Sdi1 are identified by HPV16-E6 interaction and correlate with lifespan and cellular senescence. Exp Cell Res., 247, 168-175. View in: PubMed                             

  5. Isaacs JS, Barrett JC, and Weissman BE. (1999). Interference of proteins involved in the cytoplasmic sequestration of p53 with human papillomavirus E6-mediated degradation. Mol. Carcinog., 24, 70-77.  View in: PubMed                                                                                                              

  6. Isaacs JS, Saito S, and Neckers LM (2001) Requirement for hdm2 activity in the rapid degradation of p53 in neuroblastoma. J. Biol. Chem., 276, 18497-18506.  View in: PubMed                                                                                                                                                                           

  7. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002 277(33): 29936-44. View in: PubMed                                                                                    

  8. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003 3(3):213-7.               View in: PubMed                                                                                                                                                                                                                             

  9. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J. 2003 370:1011-7.  View in: PubMed                                         

  10. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003 17(14):2115-7. View in: PubMed                                                       

  11. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. Microtubule disruption utilizes an NFkappa B- dependent pathway to stabilize HIF-1alpha protein. J Biol Chem. 2003 278(9):7445-52. View in: PubMed                                                                                                                                                             

  12. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Markovina S, Ortiz KL, Siek LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, and Gius D (2003) Geldanamycin and 17-AAG potentiate the in vitro and in vivo radiation response of cervical tumor cells via heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res., 63, 8984-8995. Veiw in: PubMed                                                       

  13. Isaacs JS, Jung YJ, Neckers L Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen- independent stabilization of hypoxia-inducible factor-1alpha by modulating an Hsp90-dependent regulatory pathway. J Biol Chem. 2004 279(16):16128-35. Veiw in: PubMed                                

  14. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004 10(18 Pt 2):6282S-9S. View in: PubMed                                                                                                                                                                                                   

  15. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L. Simultaneous inhibition of Hsp90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther. 2004 3(5):551-66. View in: PubMed                                                                                                                                                                        

  16. Isaacs JS. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up? Expert Opin Invest Drugs. 2005 14(6):569-89. View in: PubMed                                                                                                                                                                                                                 

  17. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005 8(2):143-53. View in: PubMed                                                                                                                                                         

  18. Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, Cho CH, Isaacs JS, Bae I. BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem. 2006 281(19):13047-56. View in: PubMed                              

  19. Annamalai B, Liu X, Gopal U, Isaacs JS. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol Cancer Res. 2009 7(7):1021-32. PMCID: PMC3155284. View in: PubMed                                                                            

  20. Qin Z, DeFee M, Isaacs JS, Parsons C. Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV. Virology. 2010 403(1):92-102. PMCID: PMC3202419. View in: PubMed                                                                               

  21. Bohonowych JE, Gopal U, Isaacs JS. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol. 2010 412985. PMCID: PMC2902748. View in: PubMed                                                                                                                                                                        

  22. Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLOS One. 2011 6(3):e17649. PMCID: PMC3050925 *Highlighted in Nature News: http://www.nature.com/news/2011/110802/full/news.2011.451.html.  View in: PubMed                                                                

  23. DeFee MR, Qin Z, Dai L, Toole BP, Isaacs JS*, Parsons CH* (*co-corresponding author). Extracellular Hsp90 serves as a co-factor for NF-kB activation and cellular pathogenesis induced by an oncogenic herpesvirus. American Journal of Cancer Research. 2011 1(5):687-700. PMCID: PMC3189828. View in: PubMed                                                                                                                                                                 

  24. DeFee MR, Qin Z, Dai L, Isaacs JS, Parsons CH. Interactions between Hsp90 and oncogenic viruses: Implications for viral cancer therapeutics. American Journal of Cancer Research. 2011 1(6):763-772. PMCID: PMC3195933. View in: PubMed                                                                   

  25. Bohonowych JE, Peng S, Gopal U, Hance MW, Wing S, Argraves KM, Lundgren K, Isaacs JS. Comparative analysis of novel and conventional Hsp90 inhibitors upon HIF activity and angiogenic potential in clear cell renal cell carcinoma: Implications for clinical evaluation. BMC Cancer. 2011 11:520. PMCID: PMCID: PMC3259130 View in: PubMed                                                                                                            

  26. Wu S, Dole K, Hong F, Noman AS, Liu B, Isaacs JS, and Li Z. gp96-independent inhibition of endotoxin response by chaperone-based peptide inhibitors. J Biol Chem. 2012 287(24):19896- 19903. PMCID: PMC3370174. View in: PubMed                                                                                       

  27. Hance MW, Dole K, Gopal U Bohonowych JE, Jezierska-Drutel A, Neumann CA, Liu H, Garraway IP, and Isaacs JS. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem. 2012 287(45):37732-37744, *Highlighted by Prostate Cell News as one of the top 10 noteworthy research reports. View in: PubMed                                                                                  

  28. Bohonowych JE, Hance MW, Nolan KD, Defee M, Parsons CH, Isaacs JS. Extracellular Hsp90 mediates an NF-κB dependent stromal inflammatory program: Implications for the tumor microenvironment. Under Review, Prostate. View in: PubMed                                                                        

  29. Hance MW, Gopal U, Nolan K, and Isaacs JS. eHsp90 regulates EMT from the outside: Integration of wound healing and tumor metastasis. American Journal of Cancer Research. Invited Review, In Preparation.  View in: PubMed

bottom of page